We will quote to you most important and trendy news about all kind of Therapy of the best health sites Like : "scientificamerican" and the most famous medical experts : Meghana Keshavan
daily : 2016-12-30 & on time : 10:27
according to
Experimental Cancer Therapy Makes Inroads Treating Brain Cancer
image uploaded by "scientificamerican" site
Glioblastoma is one of the deadliest cancers — an illness that responds to few treatment options, and often poorly.But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.The therapy, called CAR-T, is controversial and has faced hurdles in clinical trials.
about the details read more from here
Patient Achieves Remission With CAR-T Cell Therapy for Aggressive Brain Tumors
image uploaded by "managedcaremag" site
City of Hope researchers in Duarte, California, have successfully treated a patient with recurrent multifocal glioblastoma using MB-101 (Fortress Biotech), a chimeric antigen receptor T-cell (CAR-T) therapy, to attack cells with the interleukin-13 receptor α2 (IL13Rα2) antigen, which is common in brain cancer.City of Hope is an independent research and treatment center for cancer, diabetes, and other life-threatening diseases.A case study published in the December 29 issue of the New England Journal of Medicine outlines the results of a patient treated with his own genetically modified CAR-T cells, using central memory T cells, a stem-cell-like subset of immune cells.
about the details read more from here
City of Hope Researchers Achieve Remission Using CAR-T Cell Therapy for Aggressive Brain Tumors
image uploaded by "businesswire" site
DUARTE, Calif.--(BUSINESS WIRE)--City of Hope researchers recently reported on the successful treatment of a patient with recurrent multifocal glioblastoma using CAR-T therapy, a type of immunotherapy, to effectively attack cells with the IL13Rα2 antigen which is common in brain cancer.A case study published in the Dec. 29 edition of the New England Journal of Medicine outlined the results of a patient treated with his own genetically modified chimeric antigen receptor or CAR-T cells, using central memory T cells, a stem cell-like subset of immune cells.The 50-year-old male reported in the case study presented with recurrent multifocal glioblastoma and was enrolled in the City of Hope phase I clinical trial after failing standard of care therapy of resection, radiation and temozolomide.
about the details read more from here
No comments:
Post a Comment